This website is intended for healthcare professionals

Real-world data in Parkinson’s disease patients with motor fluctuations assesses the clinical utility of Ongentys® (opicapone)

Posted in Industry News,Sponsored Feature on 29th Apr 2021

OPTIPARK is a Phase IV, open-label study conducted in the UK and Germany under clinical practice conditions. The study assesses the clinical utility of Ongentys® 50 mg as an adjunct option to levodopa preparations in patients with Parkinson’s disease with motor fluctuations.

This article provides clinical insights from principle investigator and lead author Prof. Dr. med. Heinz Reichmann, Department of Neurology, Technische Universitaet Dresden.

UK/ON/2021/005a  Date of preparation: March 2021


Download this Article